Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OTONOMY, INC.OTIC · Entity 116495 | Director | June 21, 2022 | June 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OTONOMY, INC.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-06-20 | Direct | 27,500 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 27,500 · Balance 27,500 F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date, and (ii) the date of the Issuer's next annual meeting of stockholders occurring after the grant date, provided that the Reporting Person remains a service provider through such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Janux Therapeutics, Inc.
Report date September 13, 2024 · Filed October 24, 2024
Section 16 reporting ended · disclosed 2024-10-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,000 |
Ending reported balance
After 2024-09-13 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2024-09-13 · Exercise / conversion · Acquired 1,868 · Balance 8,868 Row 2 · 2024-09-13 · Exercise / conversion · Acquired 778 · Balance 9,646 Row 3 · 2024-09-13 · Exercise / conversion · Acquired 778 · Balance 10,424 Row 4 · 2024-09-13 · Exercise / conversion · Acquired 391 · Balance 10,815 Row 5 · 2024-09-13 · Sale · Disposed 3,815 · Balance 7,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2027-07-19 | Direct | 27,138 |
Reported balance
After 2024-09-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-09-13 · Exercise / conversion · Disposed 1,868 · Balance 27,138 F4: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.73 · Expires 2027-07-19 | Direct | 11,308 |
Reported balance
After 2024-09-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-09-13 · Exercise / conversion · Disposed 778 · Balance 11,308 F4: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2027-07-19 | Direct | 11,308 |
Reported balance
After 2024-09-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-09-13 · Exercise / conversion · Disposed 778 · Balance 11,308 F4: Immediately exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.80 · Expires 2027-07-19 | Direct | 7,682 |
Reported balance
After 2024-09-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-09-13 · Exercise / conversion · Disposed 391 · Balance 7,682 F4: Immediately exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon Ventures XI, L.P. | 2,959,175 |
Reported balance
Holding disclosure · report date 2024-09-13 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,959,175 F1: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon BioVentures I, LP | 573,227 |
Reported balance
Holding disclosure · report date 2024-09-13 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 573,227 F2: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon BioVentures SPV I, L.P. | 3,021,414 |
Reported balance
Holding disclosure · report date 2024-09-13 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 3,021,414 F3: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F2: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F3: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. The Reporting Persons disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F4: Immediately exercisable.
Synthorx, Inc.
Report date January 23, 2020 · Filed January 24, 2020
Section 16 reporting ended · disclosed 2020-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Avalon Ventures X, L.P. | 0 |
Reported balance
After 2020-01-23 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-01-23 · Other · Disposed 150,000 · Balance 0 F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon Ventures X GP, LLC | 0 |
Reported balance
After 2020-01-23 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-23 · Other · Disposed 448,567 · Balance 0 F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Avalon X SPV I, L.P. | 0 |
Reported balance
After 2020-01-23 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-01-23 · Other · Disposed 1,682,086 · Balance 0 F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.00 · Expires 2028-12-05 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-01-23 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following December 6, 2018, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2020-01-23 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-01-23 · Disposition to issuer · Disposed 15,335 · Balance 0 F3: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68). |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is a managing member of Avalon Ventures X GP LLC and Avalon Ventures X SPV GP LLC, the general partners of Avalon Ventures X, L.P. and Avalon X SPV I, L.P., and shares voting and investment power with respect to the shares held by Avalon Ventures X, L.P. and Avalon X SPV I, L.P. The Reporting Person disclaims beneficial ownership of the shares held by Avalon Ventures X, L.P., Avalon Ventures X GP LLC and Avalon X SPV I, L.P., except to the extent of his actual pecuniary interest therein if any.
F2: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following December 6, 2018, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $1,710,000.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
F3: This option, which provided for vesting of the shares in equal monthly installments over the 12 months following June 7, 2019, such that the option would be fully vested on the date of the Issuer's next annual stockholder meeting, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $852,626.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 828 | $17.00 | $14,076.00 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 13 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 1,542 | $47.74 | $73,615.08 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 12 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,880,811 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 293 | $47.74 | $13,987.82 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 11 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 546,540 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 1,511 | $47.74 | $72,135.14 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 10 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,821,470 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.28 to $47.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 46,861 | $46.42 | $2,175,287.62 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 9 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,882,353 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 8,894 | $46.42 | $412,859.48 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 8 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 546,833 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 45,894 | $46.42 | $2,130,399.48 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 7 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,822,981 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.25 to $47.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 41,661 | $47.77 | $1,990,145.97 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 6 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, LP Disclosed balance after: 2,929,214 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 7,908 | $47.77 | $377,765.16 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 5 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 555,727 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 40,803 | $47.77 | $1,949,159.31 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 4 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,868,875 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.50 to $48.14 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 50,539 | $46.78 | $2,364,214.42 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 3 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 2,970,875 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 9,592 | $46.78 | $448,713.76 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 2 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 563,635 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 26, 2024 Filed Oct 1, 2024 00:49 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 49,497 | $46.78 | $2,315,469.66 |
DisclosureSEC source: 0001415889-24-024119 · form4-10012024_121033.xml · nonDerivative · entry 1 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,909,678 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.49 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 391 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 12 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,682 Underlying: Common Stock · 391 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 778 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 11 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,308 Underlying: Common Stock · 778 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 778 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 10 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,308 Underlying: Common Stock · 778 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 1,868 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · derivative · entry 9 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,138 Underlying: Common Stock · 1,868 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 3,815 | $46.68 | $178,084.20 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 5 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 391 | $39.80 | $15,561.80 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 4 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 778 | $13.22 | $10,285.16 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 3 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 778 | $10.73 | $8,347.94 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 2 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2024 Filed Oct 24, 2024 20:15 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 1,868 | $17.00 | $31,756.00 |
DisclosureSEC source: 0001415889-24-025601 · form4-10242024_041001.xml · nonDerivative · entry 1 Lichter Jay · CIK 0001376355 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 161,356 | $47.00 | $7,583,732.00 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 9 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, LP Disclosed balance after: 3,021,414 F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 30,613 | $47.00 | $1,438,811.00 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 8 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 573,227 F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 12, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 158,031 | $47.00 | $7,427,457.00 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 7 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,959,175 F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 35,047 | $46.66 | $1,635,293.02 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 6 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, LP Disclosed balance after: 3,182,770 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 6,649 | $46.66 | $310,242.34 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 5 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 603,840 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 34,326 | $46.66 | $1,601,651.16 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 4 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,117,206 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.50 to $47.02 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 11,557 | $46.13 | $533,124.41 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 3 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 3,217,817 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,193 | $46.13 | $101,163.09 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 2 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 610,489 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 00:42 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 11,319 | $46.13 | $522,145.47 |
DisclosureSEC source: 0001415889-24-023337 · form4-09132024_120915.xml · nonDerivative · entry 1 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,151,532 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.50 to $46.47 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 277 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 12 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,073 Underlying: Common Stock · 277 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 414 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 11 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,086 Underlying: Common Stock · 414 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 414 | $0.00 Strike: $10.73 | $0.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 10 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,086 Underlying: Common Stock · 414 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionStock Option (right to buy) · Derivative | 994 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · derivative · entry 9 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,006 Underlying: Common Stock · 994 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 2,182 | $42.33 | $92,364.06 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 8 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.33 to $42.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 277 | $39.80 | $11,024.60 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 7 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 414 | $13.22 | $5,473.08 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 6 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 414 | $10.73 | $4,442.22 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 5 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 09, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | Exercise / conversionCommon Stock | 994 | $17.00 | $16,898.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 4 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · ownership.direct: The securities are directly held by Mr. Lichter. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 110,644 | $42.00 | $4,647,048.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 3 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 3,229,374 F3 · ownership.nature: The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 20,991 | $42.00 | $881,622.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 2 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 612,682 F2 · ownership.nature: The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 21:02 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 108,365 | $42.00 | $4,551,330.00 |
DisclosureSEC source: 0001415889-24-023153 · form4-09102024_090952.xml · nonDerivative · entry 1 Avalon Ventures XI, L.P. · CIK 0001652901 · 10% owner Avalon BioVentures I, LP · CIK 0001873935 · 10% owner Avalon BioVentures SPV I, L.P. · CIK 0001844550 · 10% owner Lichter Jay · CIK 0001376355 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,162,851 F1 · ownership.direct: The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 8,350 | $0.00 Strike: $39.80 | $0.00 |
DisclosureSEC source: 0001415889-24-018443 · form4-06282024_040646.xml · derivative · entry 5 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,350 Underlying: Common Stock · 8,350 shares Expires 2034-06-25 F5 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 26, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:30 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018443 · form4-06282024_040646.xml · nonDerivative · entry 1 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,083 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 26, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 691,525 | $54.75 | $37,860,993.75 |
DisclosureSEC source: 0001415889-24-015678 · form4-06052024_110623.xml · nonDerivative · entry 3 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures SPV I, L.P. Disclosed balance after: 3,340,018 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 · ownership.nature: The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 131,196 | $54.75 | $7,182,981.00 |
DisclosureSEC source: 0001415889-24-015678 · form4-06052024_110623.xml · nonDerivative · entry 2 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon BioVentures I, LP Disclosed balance after: 633,673 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 23:25 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | SaleCommon Stock | 677,279 | $54.75 | $37,081,025.25 |
DisclosureSEC source: 0001415889-24-015678 · form4-06052024_110623.xml · nonDerivative · entry 1 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Avalon Ventures XI, L.P. Disclosed balance after: 3,271,216 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The shares are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to have voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person is a managing member of Avalon XI GP and shares voting and investment power with respect to the shares held by Avalon Ventures. The Reporting Person disclaims beneficial ownership of all shares held by Avalon Ventures except to the extent of his actual pecuniary interest therein, if any. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 21:46 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | PurchaseCommon Stock | 849,854 | $5.87 | $4,988,642.98 |
DisclosureSEC source: 0001209191-23-055349 · doc4.xml · nonDerivative · entry 1 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 849,854 F1 · ownership.nature: The shares are directly held by Avalon BioVentures I, LP (ABV I). Avalon BioVentures GP LLC (ABV GP) is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. Dr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. Dr. Lichter disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:10 UTC | Janux Therapeutics, Inc. JANX · Entity 4864 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-23-037989 · doc4.xml · derivative · entry 1 Lichter Jay · CIK 0001376355 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-13 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.